TAS-102 Clinical Trials
5 recruitingDrug
Phase 12Phase 32Phase 21
Showing 1–5 of 5 trials
Recruiting
Phase 1
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Colorectal, CancerColon Adenocarcinoma
University of California, Irvine22 enrolled1 locationNCT04920032
Recruiting
Phase 3
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
Rectal CancerRectal Cancer Patients
Shandong Cancer Hospital and Institute210 enrolled1 locationNCT06850090
Recruiting
Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Gastric CancerGastroesophageal-junction Cancer
AstraZeneca572 enrolled186 locationsNCT06346392
Recruiting
Phase 2
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Colorectal, Cancer
M.D. Anderson Cancer Center25 enrolled1 locationNCT05343013
Recruiting
Phase 1
AB122 Platform Study
Colorectal, CancerEsophageal CancerGastric Cancer+6 more
Taiho Pharmaceutical Co., Ltd.917 enrolled9 locationsNCT04999761